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Cyclic guanosine monophosphate (cGMP) is an important signaling molecule and drug
target in the cardiovascular system. It is well known that stimulation of the vascular nitric
oxide (NO)-cGMP pathway results in vasodilation. However, the spatiotemporal dynamics
of cGMP signals themselves and the cGMP concentrations within specific cardiovascular
cell types in health, disease, and during pharmacotherapy with cGMP-elevating drugs are
largely unknown. To facilitate the analysis of cGMP signaling in vivo, we have generated
transgenic mice that express fluorescence resonance energy transfer (FRET)-based
cGMP sensor proteins. Here, we describe two models of intravital FRET/cGMP imaging
in the vasculature of cGMP sensor mice: (1) epifluorescence-based ratio imaging in
resistance-type vessels of the cremaster muscle and (2) ratio imaging by multiphoton
microscopy within the walls of subcutaneous blood vessels accessed through a dorsal
skinfold chamber. Both methods allow simultaneous monitoring of NO-induced cGMP
transients and vasodilation in living mice. Detailed protocols of all steps necessary to
perform and evaluate intravital imaging experiments of the vasculature of anesthetized
mice including surgery, imaging, and data evaluation are provided. An image segmentation
approach is described to estimate FRET/cGMP changes within moving structures such
as the vessel wall during vasodilation. The methods presented herein should be useful
to visualize cGMP or other biochemical signals that are detectable with FRET-based
biosensors, such as cyclic adenosine monophosphate or Ca2+, and to correlate them with
respective vascular responses. With further refinement and combination of transgenic
mouse models and intravital imaging technologies, we envision an exciting future, in
which we are able to “watch” biochemistry, (patho-)physiology, and pharmacotherapy in
the context of a living mammalian organism.
Keywords: biosensor, cremaster, cyclic GMP, dorsal skinfold chamber, fluorescence resonance energy transfer,
intravital imaging, microcirculation, multiphoton microscopy
INTRODUCTION
Blood vessels are highly organized structures consisting of vari-
ous cell types including endothelial cells in the intima, smooth
muscle cells (SMCs) in the media, and fibroblasts in the adven-
titia. These cells receive signals from surrounding tissue, blood,
and the nervous system, and they interact with each other in
multiple ways. Using ex vivo or in vitro systems, it is challeng-
ing, if not impossible, to mimic the vessel’s three-dimensional
structure, microenvironment, and physiological control systems
present in vivo. Current research aims to understand biochemi-
cal pathways contributing to vascular function and dysfunction in
health and disease. Intravital microscopy (IVM) is a powerful tool
to study signaling processes in vascular cells while still in their nat-
ural environment. IVM-based approaches have been developed to
analyze vascular structure and hemodynamic parameters in vivo,
mainly in surgically exposed tissues or through implanted optical
windows (Weigert et al., 2013). Technical innovations in confocal
and multiphoton (MP) microscopy and the generation of trans-
genic animals expressing fluorescent proteins paved the way for
state-of-the-art IVM (Jain et al., 2002; Kirkpatrick et al., 2012).
In combination with motion compensation, IVM can achieve
spatiotemporal resolutions similar to microscopy under in vitro
conditions (Lee et al., 2014).
Ca2+, cyclic adenosine monophosphate (cAMP), and cyclic
guanosine monophosphate (cGMP) are key players in the reg-
ulatory network of vascular function (Carvajal et al., 2000; De
Wit et al., 2000; Somlyo and Somlyo, 2000; Berridge, 2008;
Morgado et al., 2012). Transgenic mice were generated that
express fluorescent Ca2+ indicator proteins in endothelial cells
or SMCs (Isotani et al., 2004; Tallini et al., 2007; Mauban et al.,
2013) and cardiomyocytes (reviewed in Kaestner et al., 2014).
Interestingly, Mauban et al. recently reported that spontaneous
high-amplitude Ca2+ waves do not occur in SMCs of resistance-
type vessels in vivo, although these waves have been observed
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before in isolated vessels of various origin (Mauban et al., 2013).
This finding challenges the hypothesis that high-amplitude Ca2+
waves significantly contribute to the regulation of basal vascular
tone in vivo (Mauban et al., 2013) and highlights the impor-
tance to study cardiovascular physiology in vivo (Wier, 2014).
In contrast to Ca2+, vascular cAMP and cGMP signals have not
been visualized in vivo until now, although respective biosen-
sors have been developed and used in cells and isolated tissues
(Zaccolo et al., 2005; Nikolaev and Lohse, 2009; Thunemann
et al., 2013a). These experiments indicated the existence of subcel-
lular cyclic nucleotide compartments in cardiomyocytes and vas-
cular SMCs and a cross-modulation of cAMP and cGMP signals
in vitro (Fischmeister et al., 2006; Zaccolo and Movsesian, 2007;
Nausch et al., 2008; Stangherlin and Zaccolo, 2012). Localized
signaling domains might play important roles in cardiovascular
function and dysfunction (Nikolaev et al., 2010). In vitro exper-
iments have also shown substantial crosstalk between Ca2+ and
cyclic nucleotide signaling pathways (Carvajal et al., 2000; Feil
et al., 2003). However, the relevance of these mechanisms for the
regulation of vascular tone in vivo has yet to be demonstrated.
Cyclic GMP is generated by guanylyl cyclases in response to
nitric oxide (NO) and natriuretic peptides. Its effects are medi-
ated through cGMP-dependent protein kinases (cGKs), cyclic
nucleotide-gated ion channels, and cyclic nucleotide-degrading
phosphodiesterases. A key function of cGMP in the vasculature is
the induction of vasodilation, perhaps by modulating Ca2+ sig-
naling pathways in vascular SMCs (Lincoln et al., 2001; Beavo
and Brunton, 2002; Hofmann et al., 2006; Kemp-Harper and Feil,
2008; Francis et al., 2011). Indeed, IVM of the cremaster micro-
circulation demonstrated the importance of the NO-cGMP-cGK
pathway for dilation of resistance-type vessels in vivo (De Wit
et al., 1994; Koeppen et al., 2004). Moreover, natriuretic peptide-
induced cGMP modulates endothelial permeability, therefore
contributing to the regulation of blood volume and pressure
(Kuhn, 2012). Cyclic GMP also mediates the effects of drugs used
to treat angina pectoris (e.g., organic nitrates), erectile dysfunc-
tion (e.g., sildenafil, tadalafil), and pulmonary hypertension (e.g.,
sildenafil, riociguat) (Kemp-Harper and Feil, 2008; Schlossmann
and Schinner, 2012). Although considerable progress has been
made in unraveling cGMP’s roles in cardiovascular physiology
and pathophysiology, many of its functions remain controversial
(Feil et al., 2003, 2005; Tsai and Kass, 2009).
To extend our understanding of cardiovascular cGMP sig-
naling in vivo, we sought to establish methods that allow the
visualization of cGMP in living mice. Then, we would be able to
correlate cGMP signals with functional responses, such as vasodi-
lation, under physiological and pathophysiological conditions, or
upon pharmacotherapy with cGMP-elevating drugs. Therefore,
we generated transgenic mice expressing cGMP biosensors based
on fluorescence (or Förster) resonance energy transfer (FRET)
and reported for the first time on intravital FRET/cGMP imaging
in living mice (Thunemann et al., 2013b).
METHODOLOGY
This section describes the steps necessary to perform and
evaluate IVM experiments in the vasculature of anes-
thetized mice expressing FRET-based cGMP biosensors. We
also describe an evaluation routine that allows estimating
FRET/cGMP changes in moving structures, such as dilating
vessels. These methods are likely adaptable to experiments
within other vascular beds, e.g., in mesenteric, femoral, or
cerebral arteries, or with mice expressing other FRET-based
biosensors.
cGMP BIOSENSOR
We use the FRET-based cGMP biosensor cGi500 (“cGMP indi-
cator with an EC50 of 500 nM”) generated by Russwurm et al.
(2007). This monomolecular biosensor consists of the two cGMP-
binding sites from bovine cGK type I sandwiched between cyan
and yellow fluorescent protein (CFP and YFP). Detection of
cGMP with cGi500 is based on FRET from CFP to YFP, whose
spectra show sufficient overlap for efficient FRET (Figure 1A).
In the absence of cGMP, CFP and YFP are in favorable dis-
tance and orientation for FRET to occur, whereas cGMP binding
induces a reversible structural change of cGi500 that reduces
FRET efficiency (Figure 1B). The ratio of CFP and YFP fluores-
cence (R = CFP/YFP) recorded upon CFP excitation can be taken
as a measure for the FRET efficiency (Clegg, 2009) and, therefore,
for intracellular cGMP concentrations measured with cGi500.
It has been shown in sensor-containing cell extracts and escin-
permeabilized cells that cGi500 detects cGMP concentrations as
low as 50–100 nM and is saturated at approx. 3μMcGMP. Similar
experiments have shown that cGi500 detects cAMP only at lev-
els higher than 30μM, which exceeds typical physiological cAMP
concentrations (Russwurm et al., 2007; Thunemann et al., 2013a;
Milde and Feil, unpublished results). Based on its high selectiv-
ity for cGMP over cAMP, its dynamic range for cGMP detection,
fast kinetics, and relatively large CFP/YFP ratio changes of up
to ∼50%, the cGi500 sensor appears to be suitable for in vivo use.
TRANSGENIC MICE
Animal experiments were performed in compliance with the
guidelines for human care and use of laboratory animals.
They were approved by the Regierungspräsidium Tübingen,
the Ministerium für Energiewende, Landwirtschaft, Umwelt
und ländliche Räume des Landes Schleswig-Holstein, and local
authorities in Boston, MA. The generation of transgenic cGMP
sensor mice has been described previously (Thunemann et al.,
2013b). Transgene structures are shown in Figure 1C. Briefly, the
SM22-cGi500 mouse line was generated by random transgene-
sis using a 445-bp promoter fragment of the Transgelin/SM22
gene (Li et al., 1996) to drive cGi500 expression. The R26-CAG-
cGi500(L2) and R26-CAG-cGi500(L1) lines were generated by
targeted mutagenesis of the Rosa26 (R26) locus with a construct
derived from the R26-mT/mG targeting vector (Muzumdar et al.,
2007). IVMdata shown and discussed in this article were obtained
with the R26-CAG-cGi500(L1) mouse line that expresses cGi500
ubiquitously (Thunemann et al., 2013b).
EPIFLUORESCENCE cGMP IMAGING IN THE CREMASTER
MICROCIRCULATION
Imaging setup
• Microscope: upright Axioplan II FS (Carl Zeiss Microscopy)
with Achroplan 40×/0.75 N.A. water immersion lens. The
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FIGURE 1 | (A,B) Working principle of the FRET-based cGi500 biosensor
and (C) transgenes used to generate cGi500-expressing mice. (A) Spectral
overlap (gray) of YFP excitation (Ex, dashed lines) and CFP emission (Em,
solid lines) spectra that is necessary for FRET to occur. (B) The cGMP
indicator protein cGi500 consists of the tandem cGMP-binding sites from
bovine cGK type I (white) flanked by CFP and YFP. Without cGMP, FRET
occurs from excited CFP to YFP, leading to light emission from YFP.
Binding of cGMP (gray) causes a conformational change and a decrease in
FRET efficiency, so that light emission from YFP at 535 nm is reduced and
emission from CFP at 480 nm is increased. (B) is reproduced from
Thunemann et al. (2013b). (C) Constructs used to generate transgenic
cGi500-expressing mice. Abbreviations: E1, first exon of the endogenous
Rosa26 gene; mT, membrane-targeted tandem-dimer tomato red
fluorescent protein; neoR, neomycin resistance gene; PCAG, chicken
actin/β-globin promoter; PPGK, phosphoglycerate kinase promoter; PSM445,
445-bp promoter fragment of the Transgelin/SM22 gene; PR26,
endogenous Rosa26 promoter. Black triangles represent loxP sites, open
triangles represent FRT sites. See also Section “Selection of Appropriate
Biosensors and Generation of Biosensor-Expressing Mice” for further
details on mouse generation and characterization.
system is placed on a motorized shifting table (Luigs and
Neumann).
• Light source: Polychrome V (FEI Munich) set to 420 nm or
Spectra X with 438/24 nm light engine (Lumencor).
• Filters: 470 nm dichroic mirror (AHF). Beam splitter: Micro-
Imager DUAL-View with 516 nm dichroic mirror, 480/50 and
535/40 nm emission filters (Photometrics).
• Detector: Andor iXon 885 (Andor Technology) or Quant-EM
512sc (Photometrics) EM-CCD camera.
• Software: Live Acquisition (FEI Munich) or VisiView (Visitron
Systems).
Surgery
All surgical procedures have to be approved by the Institutional
Animal Care andUse Committee.Malemice are required for IVM
of the cremaster microcirculation.
(1) Anesthesia. Add 0.2mL midazolam (5 mg/mL, Midazolam-
Hameln, Hameln Pharmaceuticals), 0.1mL dexmedetomidin
(0.5mg/mL Dexdomitor, Lilly Germany), and 0.2mL fen-
tanyl (0.05mg/mL Fentanyl-Janssen, Janssen-Cilag) to
2.15mL Ringer’s salt solution (final concentrations:
378μg/mL midazolam, 19μg/mL dexmedetomidin,
3.8μg/mL fentanyl). The animal is anesthetized by intraperi-
toneal injection of this solution (13mL/kg body weight)
followed by continuous infusion via a jugular vein catheter
at a rate of 3mL/h/kg body weight with a syringe pump
(78–9100W, World Precision Instruments). The infusion
rate should be adjusted depending on the sedative effect
monitored by provocation tests. If the animal reacts to these
tests, increase the infusion rate initially to 4mL/h/kg body
weight, followed by a rate of 3.3mL/h/kg body weight until
the animal no longer reacts.
(2) Preparation of surgery. After injection of anesthetics, wait
20min before shaving the right scrotum, the inguinal region,
and the ventral neck region using an electric clipper (GT 420
ISIS, Aeskulap). If the animal still reacts to this manipula-
tion, apply another intraperitoneal injection of anesthetics
(5mL/kg body weight). Place the animal in supine position
on a Styrofoam stage that allows temporary fixing of tubes
and threads by needles. Maintain and monitor the animal’s
body temperature by using an electric heating mat and a
temperature monitoring system (Telemeter Electronic).
(3) Endotracheal tube for mechanical ventilation. Open the neck
by a ventral midline incision of ∼25mm length using scis-
sors. The salivary glands covering the trachea are gently
pushed aside and the trachea is isolated by blunt prepara-
tion and enlaced with two threads. Use these threads to pull
the trachea slightly upwards and cut it halfway through with
a scalpel to allow the insertion of a tube (15mm length,
I.D. 0.86mm, O.D. 1.27mm, polyethylene, Portex, Smiths
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Medical International). Push the tube 5mm down the tra-
chea and fix it using the two threads. Ensure that the animal
is still breathing and that the knots secure but do not occlude
the tube. After the animal has been moved to the imaging
setup, connect the tube to the ventilator (Minivent Type 845,
Hugo Sachs Elektronik) and start mechanical ventilation (see
Section “Imaging”).
(4) Jugular vein catheter for intravenous infusion of anesthetics.
Locate the jugular vein right to the trachea, clean it carefully
from surrounding tissue by blunt preparation, and enlace
it using three threads (Figure 2A, inset). Place one thread
caudally toward the heart and put it under little tension to
obstruct blood flow. The second thread is then positioned
cranially, closed, and knotted to obtain a sufficient length
of vein between these threads to introduce the catheter tube.
Put little tension onto both threads by fixing them temporar-
ily with needles placed into the Styrofoam. Use fine scissors
(Fine Science Tools) to open the jugular vein halfway. Use a
27-gauge cannula (0.40 × 20mm, Sterican, Braun) bend by
90◦ and attached to a 1-mL syringe to open the vein. Carefully
insert a saline-filled polyethylene tube (I.D. 0.26mm, O.D.
0.61mm, Portex, Smiths Medical International) beneath the
cannula. Release the caudal thread, push the tube about
10mm toward the heart, and secure the catheter using all
three threads. Usually it is possible to verify correct position-
ing by blood aspiration. Close the wound by three single cuta-
neous sutures and start continuous infusion of anesthetics at
a rate of 3mL/h/kg body weight as described above.
(5) Cremaster preparation. Place the mouse in supine position
on a custom-made animal stage that is later used for IVM
(Figure 2A). Push the right testicle down into the scrotum.
Cut a hole into the scrotum at its peak using scissors, insert
one blade, and open the scrotum along its length toward
the inguinal region. The cremaster muscle is now visible
and requires continuous moistening; start dropping warmed
(34◦C) salt solution at a rate of 3mL/min from a reservoir
onto the muscle. The salt solution contains (in mmol/L):
118.4 NaCl, 20 NaHCO3, 3.8 KCl, 2.5 CaCl2, 1.2 KH2PO4,
and 1.2 MgSO4; it is gassed with 5% CO2 and 95% N2
to adjust the pH to 7.4. Mobilize the peak of the muscle
pouch and secure it using an atraumatic thread (Serapren
6/0, Serag-Wiessner). Establish a constant fluid flow over the
muscle (superfusion) for 10min to soak and visualize con-
nective tissue. Then, carefully clean the muscle from this
connective tissue. Do not cut into muscle tissue and use the
initially placed thread to elevate the cremaster to access its
bottom side. Now, the muscle pouch is spread over the glass
window that is part of the stage. Around this window, a sil-
icon wall holds the threads fixing the edges of the muscle
(Figure 2A). Pull the thread attached to the cremaster’s peak
through the silicon wall and apply some tension to pull the
muscle pouch over the window. Use scissors to cut a small
hole into the pouch at its peak, insert one blade, and cut it
open up to the inguinal region. Avoid cutting through larger
vessels that usually lay at the bottom of the pouch. Use 2–3
atraumatic threads at each side to fix the lateral edges of
the muscle; apply some tension to flatten the cremaster over
the glass window (Figure 2A). Cut the ligament between cre-
master and testis to allow repositioning of the testis into the
abdominal cavity, which requires cutting one pair of a larger
arteriole and vein that enters through this ligament into the
testis. Subsequent bleeding will usually cease after a short
period. Hemostasis can also be achieved using collagen-based
hemostatic sponges.
(6) Isolation of arterioles. For particular experiments, arteri-
oles can be freed from surrounding striated muscle (see
Result Section “Imaging of cGMP within the Cremaster
Microcirculation” and Figure 2C). This procedure requires
a surgical microscope with 40-fold magnification (Wild
Heerbrugg) and fine preparation tools. Cut into the skele-
tal fibers that lay on top of the vessels and strip the fibers
away using fine forceps. Only isolate small (1–2mm) arteriole
sections for better viability.
Imaging
(1) Place the animal stage onto themicroscope andmove the cre-
master muscle into the light path. Do not interrupt superfu-
sion of salt solution for longer than 30 s. Attach the ventilator
and start mechanical breathing with a frequency of 160 per
min and a stroke volume of 225μL. Check connections of
the jugular vein catheter and the level of anesthesia.
(2) Move the objective lens to working distance and adjust
the rate of superfusion to 8mL/min. The solution is deliv-
ered onto the water immersion objective to form a flowing
“drop” between lens and specimen. To provide a physiologic
environment, the superfusate is kept at low oxygen tension
by gassing with 5% CO2/95% N2 before and throughout
the experiment as well as by using gas-impermeable plas-
tic or glass tubes. Gravity-driven superfusion from a reser-
voir avoids pulsatile flow, but care has to be taken that the
rate of superfusion stays constant throughout the experi-
ment, particularly if drugs are applied through a roller pump
(Miniplus3, Gilson). The roller pump delivers drugs into
the main superfusion tube just before the fluid reaches the
objective. The delivery rate of the roller pump is set to
0.08mL/min. Thus, drugs delivered by this pump are diluted
100-fold just before they reach the specimen. Vehicle (e.g.,
water) should be delivered if no drug is applied. Check for
continuous removal of the superfusate to avoid leakage into
the microscope.
(3) Select an appropriate region using bright field and flu-
orescence illumination. Identify vessel types by diameter,
wall structure, and direction of blood flow that diverges in
branching arterioles but converges in branching venules.
(4) Select illumination time and intensity, as well as camera
gain and binning to obtain images with sufficient signal-
to-noise ratios, while avoiding excessive photobleaching.
Settings depend on the imaging setup as well as the biosen-
sor that is used, and its expression level. Parameters have
to be optimized for individual setups and according to
experimental demands (e.g., temporal vs. spatial resolu-
tion). Representative acquisition parameters for the setup
described in Section “Imaging setup” are given in the legend
to Figure 2F.
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FIGURE 2 | Imaging of cGMP within the cremaster microcirculation.
(A) A custom-made acrylic glass stage holds the anesthetized mouse in
supine position on a heating pad (not shown). The cremaster muscle has
been surgically exteriorized and fixed with atraumatic threads on top of a
coverslip (light blue). Threads are pinned through a silicone wall that
surrounds the coverslip as a semicircle. The cremaster is superfused with
pre-warmed (34◦C) salt solution delivered along the objective lens (not
shown) approaching the cremaster from top. The solution is drained
through the outlet at the bottom of the stage. For mechanical ventilation, a
tube has been inserted into the trachea. A detailed depiction of jugular vein
cannulation is shown in the inset. (B) Arteriole within the intact cremaster
muscle of a R26-CAG-cGi500(L1) mouse. B.1 shows the vessel before and
B.2 during superfusion of 10μM DEA/NO that causes vasodilation.
Estimation of cGMP levels was not possible under this condition, because
strong fluorescence from striated muscle prevented FRET measurements
within the vessel wall. (C) After removal of striated muscle, walls of
cremaster arterioles of a R26-CAG-cGi500(L1) mouse are clearly visible, but
they lost their basal tone and did not dilate upon superfusion with DEA/NO
or other vasoactive drugs. (D) In an intact cremaster preparation of a
R26-CAG-cGi500(L2); SMA-CreERT2 double-transgenic mouse, only the
vessel walls show cGi500 expression. The animal was treated for 5 days
with 1mg tamoxifen (i.p.) per day to induce CreERT2-mediated activation of
the R26-CAG-cGi500(L2) transgene specifically within SMCs. The image
was taken 1 week after the last tamoxifen injection. (E) Definition of ROIs
(arteriole: white outline; background region: gray, “Bg”) for cGMP imaging
in the cremaster of a R26-CAG-cGi500(L1) mouse after removal of striated
muscle. (F) Cyclic GMP imaging of the arteriole shown in (E); the black
trace indicates baseline-normalized CFP/YFP ratio changes (R/R)
(Continued)
FIGURE 2 | Continued
representing intracellular cGMP levels; cyan and yellow traces represent
baseline-normalized CFP and YFP fluorescence intensity changes (F/F).
Repeated application of 10μM DEA/NO induced reversible cGMP
transients, while 10μM adenosine (Ado), known to induce relaxation via the
cAMP pathway, did not induce detectable ratio changes. Antiparallel
changes of CFP and YFP intensities are indicative for true changes of
cGi500 FRET efficiency. Asterisks denote artifacts due to focus drift.
Acquisition parameters were as follows: excitation: Polychrome V at
420 nm; objective: 40×; acquisition frequency: one image every 0.5 s;
camera: Andor iXon 885 with 2 × 2 binning (251 × 501 pixels) and gain set
to 25; exposure time: 150ms. Temporal binning of six frames was done
before evaluation performed by subtraction of a background region.
Evaluation via image segmentation led to similar results but lower R/R
values (not shown). All images (B–E) were obtained at 40× original
magnification. Panels E and F are reproduced from Thunemann et al.
(2013b) and show representative results from experiments with three
animals.
(5) Acquire time series under basal conditions to estimate signal-
to-noise levels and to observe potential baseline drift or basal
activity of the cells under investigation.
(6) After a stable baseline is recorded for a sufficient period
(e.g., for 30–60 frames), drugs (e.g., the NO-releasing drug
DEA/NO) can be applied via superfusion using the roller
pump. Exchange vehicle with drug solution to start applica-
tion and back to vehicle to terminate application. The time
delay until the drug reaches the specimen can be estimated
by sucking air into the tube of the roller pump. Observe the
air bubble moving through the tube and measure the time
until its delivery.
(7) During the imaging session, check anesthesia and vital
parameters from time to time. Based on our experience,
IVM can be performed for up to 6 h. At the end of the
experiment, apply a lethal dose of pentobarbital (1 g/kg body
weight, e.g., 6.25mL/kg body weight of a 160mg/mL pento-
barbital solution, Narcoren, Merial) through the jugular vein
catheter.
MULTIPHOTON cGMP IMAGING IN SUBCUTANEOUS VESSELS USING
THE DORSAL SKINFOLD CHAMBER
Imaging setup
Details on this IVM setup have been described previously (Brown
et al., 2001).
• Microscope: upright BX51WI (Olympus) with Fluoview
FV300 scanning system and 20×/0.95 N.A. water immersion
lens. The system is placed on a vibration-free table (Melles
Griot) within a light-tight enclosure.
• Light source: MaiTai Ti:Sapphire laser (Spectra-Physics) pro-
viding 100 fs pulses at 80MHz repetition rate and 850 nm
wavelength with a power of 36mW at the sample surface.
• Filters: 750 nm short pass dichroic mirror (Chroma). FRET fil-
ter set: 505 nm long pass dichroic mirror (Chroma), 483/32 nm
and 542/27 nm emission filters (Semrock).
• Detection: HC125-02 photomultiplier tubes (Hamamatsu
Photonics).
• Software: FluoView (Olympus).
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Surgery
All surgical procedures have to be approved by the Institutional
Animal Care and Use Committee. The procedure follows the pro-
tocol for implantation of dorsal skinfold chambers (DSCs) in
mice as described in Leunig et al. (1992).
(1) Anesthetize mice by intraperitoneal injection of 90mg/kg
body weight ketamine and 9mg/kg body weight xylazine.
Wait ∼15min until the animal does not react to provocation
tests anymore. During the surgical procedure, maintain the
animal’s core body temperature at 36–37◦C using a heating
pad. Apply a lubricant to prevent corneal dehydration.
(2) Shave and depilate the entire back of the animal prior to
chamber implantation.
(3) Gently stretch the double layer of the skin from the back
of the mouse and implant two symmetrical titanium frames
(weight 3.2 g; produced at the workshop of the Department
of Radiation Oncology, MGH)making mirror images of each
other to sandwich the skin. Place sutures in the top part of the
skin through the holes at the top edge of the titanium frames
to hold the frames in place.
(4) Remove one layer of the skin in a circular area of 15mm in
diameter. To stop bleeding, apply gentle pressure using a cot-
ton swab. Cover the remaining layer consisting of epidermis,
subcutaneous tissue, and striated muscle with a glass cover-
slip incorporated into a depression in one of the frames. Hold
the coverslip in place with a retaining ring (Figure 3A).
(5) Allow the animal to recover for at least 48 h. For analgesia,
administer 0.05–0.1mg/kg body weight buprenorphine every
12 h subcutaneously for 3 days, and thereafter as needed.
Animals loose about 15% of their body weight within the first
48 h after DSC implantation and further weight loss or other
signs of distress are usually not observed (Leunig et al., 1992).
If there is any sign of inflammation, redness, fluid accumula-
tion, edema, etc. in the DSC, animals are further observed for
recovery or excluded from the study.
Imaging
IVM has to be performed with approval by the Institutional
Animal Care and Use Committee.
(1) Anesthetize a mouse with DSC by subcutaneous or intraperi-
toneal injection of ketamine/xylazine (90/9mg/kg body
weight). Alternatively, gas anesthesia such as 1–1.5% isoflu-
rane in medical air can be used. Properly maintained gas
anesthesia is more stable and suitable for long and/or
physiological imaging studies.
(2) Place the anesthetized animal on a heated microscope stage.
Apply a lubricant to prevent corneal dehydration. Clamp the
chamber to a custom-built metal frame on the microscope
stage. For drug application, place an intravenous catheter
connected to a 1-mL syringe filled with 0.9% NaCl into the
tail vein. The catheter consists of a 30-gauge needle connected
to polyethylene tubing (PE-10, BD Medical, I.D. 0.28mm,
O.D. 0.61mm) of appropriate length (see below). Fix the
catheter needle with a small drop of superglue to the tail and
the tubing with adhesive tape to the microscope stage.
(3) Place the animal-bearing stage on the imaging setup. The
syringe connected to the catheter must later be accessible
without disturbing image acquisition. Place a drop of water
on the coverslip of the DSC and move the objective into
working distance. Select an appropriate region under bright
field illumination. Check the animal’s vital parameters and
close the enclosure. Examine the field of view under fluo-
rescence illumination and fine-adjust x/y-position and the z
focus.
(4) Prepare image acquisition: adjust illumination intensity,
scan speed, zoom, and photomultiplier voltage to obtain
images with sufficient signal-to-noise ratios. Image acqui-
sition may not cause excessive bleaching of the biosensor.
Settings have to be optimized according to the IVM setup,
the respective biosensor and its expression level, as well
as experimental demands (e.g., temporal vs. spatial resolu-
tion). Representative acquisition parameters for the setup
described in Section “Imaging setup” are given in the legend
to Figure 3E.
(5) Acquire time series under basal conditions to estimate signal-
to-noise levels and to observe potential baseline drifts or basal
activity of the cells under investigation.
(6) After a stable baseline is recorded for a sufficient period (e.g.,
for 20–30 frames), substances are applied through the tail
vein catheter. Apply vehicle (saline or PBS) and then test
compounds (e.g., the NO-releasing drug DEA/NO); consider
the catheter’s death volume.
(7) Ketamine/xylazine anesthesia typically lasts for 30–40min;
check regularly for vital functions and state of conscious-
ness during the imaging session. If necessary, inject ketamine
again; use half of the initial dose. The animal should not
be anesthetized for more than 1 h. After imaging, carefully
remove the catheter from the tail and allow the animal to
recover in its home cage. We recommend performing imag-
ing experiments not more frequently than every other day.
IMAGE SEGMENTATION WITH A BINARY MASK AND DATA
EVALUATION
Image processing is performed using the open source software
ImageJ or ImageJ-derived software (Schneider et al., 2012). In
establishing this protocol, the data were evaluated manually,
although ImageJ and other software packages (e.g., Metamorph,
IDL, Matlab) have built-in functions and routines for automa-
tion. Handling of time-lapse image series may require large
amounts of free working memory; therefore, data evaluation
should be performed on computers equipped with ≥8GB RAM.
(1) Image preprocessing. Save CFP and YFP time series as files
readable by ImageJ (http://imagej.nih.gov/ij/) or ImageJ-
derived distributions like Fiji (http://fiji.sc/Fiji). Open the
time series and check for correct alignment of CFP and
YFP channels. If necessary, apply corrections like man-
ual or automatic alignment procedures (see, e.g., Kardash
et al., 2011; Pitkeathly et al., 2012). Signal-to-noise ratios
can be improved by spatial or temporal binning (method:
“sum” or “average”) that on the other hand will lead to
loss of spatial or temporal resolution. Thereafter, intensities
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FIGURE 3 | Imaging of cGMP in subcutaneous vessels using the dorsal
skinfold chamber (DSC). (A) Schematic drawing of a mouse with implanted
DSC. (B) Field of view observed with MP microscopy through the DSC used
for cGMP imaging as shown in (C–E). (B) shows the tissue before DEA/NO
injection. Scale bar: 100μm. (C) Image from the dynamic binary mask
showing the tissue shortly after DEA/NO injection. (D) Kymograph showing
movements of the vessel wall at the cross-section indicated by dashed red
lines in (B,C) (time increases from left to right). Vasodilation was solely
caused by movement of the upper vessel wall (left wall in B,C). (E) Cyclic
GMP imaging of the (yellow) ROI outlined in (B,C). The black trace shows
changes of the baseline-normalized CFP/YFP ratio (R/R) upon three
intravenous injections of 0.1mM DEA/NO followed by two injections of 1mM
DEA/NO. Few time points were omitted due to disturbance of image
acquisition by ambient light. The relative vessel diameter change (d/d, red
trace) was determined from the kymograph shown in (D). Acquisition
parameters were as follows: excitation: 850 nm with 36mW at the tissue
surface; objective: 20×; acquisition frequency: one image every 5 s; image
size: 512 × 512 pixels (707.11 × 707.11μm). (B,E) are reproduced from
Thunemann et al. (2013b). Representative results from five experimental
sessions with three animals are shown.
from a background region can be subtracted and baseline
normalization can be performed as described previously
(Thunemann et al., 2013a). To account for tissue motion
during image acquisition, we suggest performing image seg-
mentation.
(2) Image segmentation with a dynamic binary mask. This
routine derived from a strategy originally described by
Zhang et al. (2010) is performed to follow CFP/YFP ratio
changes in moving structures, such as the vessel wall during
vasodilation. Subsequent steps and Figure 4 describe how the
dynamic binary mask is generated und used:
• Apply the “threshold” function to the raw CFP or the
raw YFP time series; select the lower threshold so that
the structure of interest is above the threshold throughout
the whole time series (perform “stack histogram func-
tion”). If CFP and YFP time series differ in quality (e.g.,
in signal-to-background ratios), use the series of higher
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quality, but make sure that decreased fluorescence caused
by FRET efficiency changes do not cause the structure of
interest to fall below the threshold.
• The final binary mask is generated by dividing the thresh-
olded time series by itself using the “Image Calculator”
function with the “32-bit (float) result” option enabled.
The resulting dynamic binary mask has only values of “1”
(pixels above threshold) or “NaN” for “not a number”
(pixels below threshold).
• Apply this mask to both time series using the “Multiply”
operation within the “Image Calculator” function. In the
resulting segmented CFP and YFP time series, bright struc-
tures above the threshold possess intensity values as in the
original time series, while dim/non-fluorescent structures
below the threshold have “NaN” values (Figure 4).
• Note that background fluorescence (set to “NaN”) is
not subtracted from pixels above the threshold (see
also discussion in Section “Multiphoton cGMP Imaging
of Subcutaneous Vessels Using the Dorsal Skinfold
Chamber”).
(3) ROI definition and extraction of CFP and YFP intensities.
Draw regions defining the target structure during the whole
experiment considering shape changes and movements. As
“NaN” pixels do not contribute to the region’s average inten-
sities, ROIs may contain large proportions of background
fluorescence. Add regions to the “ROIManager” and perform
the “Multi Measure” command twice to extract mean intensi-
ties from both channels. Transfer values to Excel (Microsoft)
or Origin (OriginLab) for further evaluation as described
(Thunemann et al., 2013a).
(4) Generation of time-lapse ratio images. Pixel-by-pixel
CFP/YFP ratio series representing cGMP levels are calculated
by dividing thresholded time series by each other using the
“Image Calculator” function.
(5) Estimation of vessel diameter. To estimate changes in vessel
diameter, draw a line orthogonal to the direction of blood
flow into the dynamic binary mask. The line has to cover
both vessel walls throughout the experiment. Generate a
kymograph using the “Reslice” command within the “Stacks”
menu with the “Rotate by 90 degrees” option enabled.
The resulting image shows the time series at the cross-
section of the vessel wall with time increasing from left to
right (Figure 3D) and can be used for manual or semi-
automatic vessel diameter estimation. Kymographs derived
from CFP/YFP ratio series show changes in cGMP levels and
vessel diameter within the same image.
RESULTS AND DISCUSSION
SELECTION OF APPROPRIATE BIOSENSORS AND GENERATION OF
BIOSENSOR-EXPRESSING MICE
Two designs of genetically encoded biosensors are commonly
used. One class includes monomolecular FRET-based biosensors
like cGi-type cGMP sensors that contain donor and acceptor flu-
orophore in a single polypeptide chain. Other biosensors, such as
FlincG-type cGMP sensors (Nausch et al., 2008; Bhargava et al.,
2013) or Ca2+ sensors of the GCaMP family (Tian et al., 2009;
Chen et al., 2013), contain circularly permutated green fluores-
cent protein (cpEGFP). Monomolecular FRET-based biosensors
can be measured by simultaneous acquisition of donor and
acceptor emission upon donor excitation. In camera-based sys-
tems, beam splitters should be used to direct donor and acceptor
fluorescence to two separate cameras or onto the halves of a
single camera chip. In scanning microscopes, emitted light is
detected by two separate photomultiplier tubes. Emission of
cpEGFP-based biosensors can bemeasured at a single wavelength.
Potential advantages and disadvantages of FRET- and cpEGFP-
based biosensors are discussed in more detail in Newman et al.
(2011), Kaestner et al. (2014). Ideally, any change in biosen-
sor fluorescence should originate from ligand binding, but not
from other processes that affect fluorescence intensity recordings,
such as motion of the target structure. In this regard, ratio-
metric FRET-based biosensors are advantageous over cpEGFP-
based biosensors, because not a single fluorescence intensity
(e.g., EGFP) but the ratio between two simultaneously recorded
fluorescence intensities (e.g., CFP/YFP) is taken to estimate lig-
and binding to the sensor. Artificial intensity changes will not
affect quantification as long as both donor and acceptor flu-
orescence are affected to the same extent. This should be the
case, for instance, upon movement of the imaged tissue due to
vasodilation, heartbeat, blood flow, or breathing.
Biosensor-expressing transgenic mice are important tools for
IVM. Expression of the biosensor must be appropriate for its
detection with sufficient signal-to-noise ratios. Initially, we used
random transgenesis to generate cGi500-expressing mice, which
is a relatively simple method in terms of transgene assembly and
mouse generation. However, it often requires screening of many
founder lines to identify lines with stable and sufficient transgene
expression. Using an appropriate promoter is critical for success-
ful generation of such a transgenic mouse line. Unfortunately,
random integration of the transgene into the genome often leads
to unpredictable and unwanted expression patterns. We used the
445-bp promoter fragment of the Transgelin/SM22 gene (Li et al.,
1996) to generate SM22-cGi500 mice with SMC-specific cGi500
expression (Figure 1C upper). Among 11 founder lines, one
mouse line showed stable SMC-specific cGi500 expression (data
not shown). The expression level of cGi500 in SMCs derived from
aorta, colon, and bladder is heterogeneous with ∼25% of the cells
showing relatively strong cGi500 expression (Thunemann et al.,
2013b). However, SM22-cGi500 mice do not express detectable
cGi500 levels in cremaster arterioles (Thunemann et al., unpub-
lished data), so that these mice cannot be used for cGMP imaging
in the cremaster microcirculation.
To generate mice with strong and homogeneous cGi500
expression, we used targeted mutagenesis to integrate a Cre-
dependent cGi500 expression cassette into the R26 gene locus
(Figure 1C middle). This gene locus is known for transcriptional
accessibility in most if not all cell types throughout pre- and
postnatal development (Soriano, 1999). Although technically
more challenging, generation of R26 knock-in mice became
a popular approach to express fluorescent proteins including
biosensors (Zariwala et al., 2012; Abe et al., 2013; Batti et al.,
2013). To increase biosensor expression above the relatively
low levels that are usually achieved with the endogenous R26
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FIGURE 4 | Image segmentation approach to evaluate time-lapse series
of moving structures. (1) A threshold is applied to the raw CFP time
series to generate a dynamic binary mask. The raw YFP series can also be
used, but only one mask (from CFP or from YFP) is required. Numbers
within the raw images represent virtual pixel intensities; in this example,
the threshold was set to an intensity of 50. Now, target structures with
intensities above the threshold receive the value “1” (white), while
dim/non-fluorescent structures below the threshold receive the value
“NaN” for “not a number” (blue), that does not equal “0.” (2) Image
segmentation is performed by multiplication of the same dynamic binary
mask with the original raw CFP and YFP time series. Within segmented
time series, pixels representing (bright) target structures retain their
original intensities, while pixels representing dim/non-fluorescent structures
are now set to non-numerical values (“NaN,” blue). (3) CFP and YFP
intensity changes are extracted from segmented time series in a region of
interest (ROI, red) that contains the moving vessel wall throughout the
whole time series. “NaN” pixels do not contribute to the ROI’s mean
intensities. (4) Segmented CFP and YFP time series are used to calculate
pixel-by-pixel CFP/YFP ratio series. As background is set to “NaN,” ratio
series do not suffer from artifacts occurring when noisy images are divided
by each other. The dynamic binary mask can also be used to estimate
changes in vessel diameter (see Figure 3D).
promoter in adult mice, the strong chicken actin/β-globin
(CAG) promoter (Niwa et al., 1991) can be integrated into
the R26 knock-in transgene. Activation of sensor expression is
achieved by breeding mice carrying the R26 knock-in transgene
to cell type-specific Cre-transgenic mouse lines. This strategy
should allow one to direct high and homogeneous levels of
biosensor expression to almost any cell type of interest. We
have generated R26 knock-in mice carrying the Cre-dependent
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R26-CAG-cGi500(L2) transgene (Thunemann et al., 2013b).
We observed strong and tissue-specific cGi500 expression in
mice generated by breeding R26-CAG-cGi500(L2) mice with
tissue-specific Cre mice (Figure 2D, and Wen, Thunemann,
Feil, unpublished results). This finding is in line with numer-
ous reports on other Cre-inducible R26 knock-in transgenes
(Casola, 2010). Furthermore, we transfected embryonic stem
cells carrying the R26-CAG-cGi500(L2) transgene with a Cre
expression plasmid to generate the permanently activated R26-
CAG-cGi500(L1) transgene (Figure 1C lower). Indeed, mice
established from R26-CAG-cGi500(L1) embryonic stem cells
showed strong cGi500 expression in virtually all tissues and cell
types examined (Thunemann et al., 2013b). Importantly, use of
the CAG promoter resulted in high cGi500 expression levels and
sufficient fluorescence intensities for in vivo imaging experiments
(Figures 2, 3, 5). We conclude that the wide use of the Cre/lox sys-
tem and the availability of hundreds of Cre mouse lines combined
with the positive experience using the R26 locus as knock-in
target, the generation of biosensor-expressing mice via Cre/lox-
activatable R26 knock-in transgenes is an attractive alternative to
random transgenesis.
When working with biosensor-expressing cells, tissues, and
mice, it is important to consider potential side effects of sen-
sor expression. A biocompatible sensor should not interfere
with normal physiology. The cGi500 sensor contains the cGMP-
binding sites of cGK type I, but not its catalytic kinase domain
nor its N-terminal region that interacts with various proteins
(Figure 1B). Although we cannot formally exclude that cGi500
acts as an intracellular cGMP buffer, we did not observe any
adverse effects of its expression on the health of cGi500-transgenic
mice nor on the functions of cells isolated from these mice
(Thunemann et al., 2013b). In this context, it is interesting to
note that mice expressing a FRET-based Ca2+ sensor in a ubiqui-
tous manner show only relatively mild phenotypes (Direnberger
et al., 2012). However, when mice express a biosensor with enzy-
matic activity, for instance, myosin light chain kinase activity
in MLCK Ca2+ indicator mice (Isotani et al., 2004), it might
be important to exclude interference of the sensor with nor-
mal physiology by reducing its expression level as much as
possible.
IMAGING OF cGMPWITHIN THE CREMASTER MICROCIRCULATION
The mouse cremaster is a relatively transparent skeletal muscle
(∼200μm thick) that forms a pouch around the testis and con-
tains resistance-type vessels. The first in vivo study of vascular
responses within the cremaster was published in 1964 (Grant,
1964). Most current protocols for cremaster IVM, including those
presented herein, follow the procedure described by Baez (1973),
which includes the opening of the cremaster muscle, its detach-
ment from the testicle, and the spreading of the cremaster to a
flat sheet (Figure 2A). A number of studies used biosensors to
visualize Ca2+ in endothelium and SMCs of cremaster arterioles.
However, the functional role of cGMP in the cremaster micro-
circulation has so far been studied only indirectly, for instance,
by analyzing vasodilation or vascular permeability in mouse lines
with mutations of components of the cGMP signaling pathway
(Koeppen et al., 2004; Chen et al., 2012).
Using the cGi500 sensor, we were able to visualize changes in
cGMP concentrations in cremaster arterioles in vivo (Thunemann
et al., 2013b). Experiments were performed with the R26-CAG-
cGi500(L1) mouse line showing ubiquitous cGi500 expression.
Accordingly, we observed cGi500 expression in the vessel wall and
in the striated muscle of the cremaster itself, in which vessels are
embedded, as well as in circulating blood cells (Figures 2B,C,E,
and data not shown). Application of the NO-releasing drugs
sodium nitroprusside and DEA/NO, as well as adenosine and
acetylcholine induced dilation of cremaster arterioles (Figure 2B,
and data not shown). However, attempts to detect DEA/NO-
induced cGMP signals in arterioles of the intact cremaster prepa-
ration (as shown in Figure 2B) failed due to strong cGi500
fluorescence in striated muscle (data not shown). After surgi-
cal removal of the skeletal muscle from arterioles (Figures 2C,E),
robust CFP/YFP ratio changes indicating reversible cGMP eleva-
tions could be observed in the vessel wall upon superfusion of
DEA/NO, while adenosine did not cause a detectable cGMP ele-
vation (Figure 2F). However, because vessels that were isolated
from surrounding tissue apparently lost their basal tone and did
not dilate upon drug superfusion, this experimental setup did not
allow us to correlate cGMP levels with the extent of vasodilation.
Moreover, because of ubiquitous cGi500 expression in R26-CAG-
cGi500(L1) mice, it is difficult to allocate cGMP signals to specific
vascular cell types. Thus, this model has two limitations related
to ubiquitous sensor expression. Firstly, FRET recordings are dis-
turbed by fluorescence from striated muscle and, secondly, it is
difficult to pinpoint cGMP signals to specific vascular cell types.
Both problems could be avoided by cell type-specific cGi500
expression within distinct cell types of the cremaster microvas-
culature. Therefore, the Cre-responsive R26-CAG-cGi500(L2)
mouse line is currently bred with endothelium- or SMC-specific
Cre lines (Figure 2D, and data not shown). Furthermore, by using
other Cre-transgenic lines, it should be possible to visualize cGMP
signals in various other cell types, for instance, in leukocytes dur-
ing inflammatory processes or in platelets during adhesion to the
vessel wall and thrombus formation.
Advantages of the open cremaster model for IVM are its out-
standing optical quality and relativelyminormotion artifacts. The
good accessibility of arterioles within the exteriorized cremaster
allows direct drug delivery via superfusion or locally via glass
pipettes. Applying drugs only to the tissue of interest and not
systemically through intravenous infusion can be an advantage.
Continuous superfusion almost instantaneously removes drugs,
allowing for studies with many successive drug applications, for
example, to generate concentration-response curves or to com-
pare effects of different drugs. On the other hand, cremaster IVM
requires supported breathing, continuous delivery of anesthetics,
temperature maintenance with external heat sources, and con-
stant superfusion with gassed salt solution. The time required to
prepare an animal for imaging is around 1 h, and the time for
experiments is limited to about 6 h per animal.
MULTIPHOTON cGMP IMAGING OF SUBCUTANEOUS VESSELS USING
THE DORSAL SKINFOLD CHAMBER
The DSCmodel (Figure 3A) has been established to study tumors
implanted below the chamber window. In addition, this method
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FIGURE 5 | Subtraction of a background region vs. image
segmentation for evaluation of ratiometric FRET/cGMP imaging data.
Traces show baseline-normalized CFP/YFP ratio changes (R/R; white) or
baseline-normalized CFP and YFP intensity changes (F/F; cyan and
yellow, respectively). (A) Evaluation of epifluorescence recordings of
cGi500-expressing cultured vascular smooth muscle cells (VSMCs) isolated
from R26-CAG-cGi500(L1) mice. White bars indicate superfusion with
100 nM DEA/NO. Upon subtraction of a background region (left, gray ROI),
selection of a large ROI (yellow) containing a high proportion of
dim/non-fluorescent background increases noise (upper left) as compared
to a small ROI (red) containing mainly the fluorescent cell (lower left).
Applying image segmentation (right, see Figure 4 for further details) with
the same ROIs results in lower F/F and R/R changes. The noise levels
are not affected by the proportion of dim/non-fluorescent background
within a ROI and thus, results are the same for small and large ROI. Scale
bar, 50μm. (B) Evaluation of in vivo FRET/cGMP recordings obtained from
subcutaneous vessels via MP microscopy through a DSC; numbers in
brackets indicate bolus drug applications: (1): 100μL 0.9% NaCl; (2), and
(3): 100μL 1mM DEA/NO. The image was taken right before the first
DEA/NO injection. Subtraction of a background region (left, gray ROI in top
right corner) is not suitable for evaluation, because DEA/NO-induced
vasodilation causes massive drops in fluorescence intensities due to an
increased contribution of dim/non-fluorescent vessel lumen to the ROI
defining the vessel wall (yellow). This large drop obscures comparably
small alterations in CFP and YFP fluorescence caused by cGMP-induced
changes in FRET efficiency. When image segmentation is used (right),
dim/non-fluorescent structures do not contribute to mean ROI intensities,
leading to much smaller drops in CFP and YFP fluorescence, and
cGMP-induced R/R changes are revealed. Scale bar: 100μm. (B) is
modified from Thunemann et al. (2013b).
allows imaging of the tumor environment, for instance, to mon-
itor changes in vascularization during tumor growth (Brown
et al., 2001). IVM studies with DSCs were initially performed
with bright field, epifluorescence, or confocal microscopy, but
nowadays, MP microscopy is primarily used. MP excitation has
several advantages over single photon excitation: out-of-focus
fluorescence above or below the focal plane is avoided, excitation
with pulsed infrared lasers allows for larger penetration depths
(up to ∼0.5mm tissue), and the infrared light causes compar-
atively mild damage to fluorescent molecules and surrounding
tissue (Helmchen and Denk, 2005).
We implanted DSCs into R26-CAG-cGi500(L1) mice and
used them for MP-FRET/cGMP imaging (Thunemann et al.,
2013b). Subcutaneous vessels were readily visible and, in con-
trast to the cremaster model, we were able to identify regions
where surrounding tissue did not interfere with the detec-
tion of FRET/cGMP signals from vessel walls (Figures 3B,E).
Mice received vasoactive drugs as bolus injections via a tail
vein catheter. In our experiments, 3–5 drug applications were
performed over 15–30min. In studies with cultured cells
and cremaster arterioles, the initial steps in image evaluation
are ROI definition and subtraction of a dim/non-fluorescent
background region (see Figure 2E). When we subtracted intensi-
ties from a background region, vasodilation strongly confounded
the analysis of CFP/YFP ratio signals within the vessel wall
(Figure 5B left). Vasodilation led to an increase in the proportion
of dim/non-fluorescent vascular lumen within the ROI that
resulted in strong and parallel reductions of CFP and YFP
fluorescence. These drops were much stronger than any intensity
changes caused by cGMP binding to cGi500 (Figure 5B left). To
overcome this problem, we performed image segmentation with
a dynamic binary mask (Figure 4). Here, instead of subtracting
a background region, structures with a brightness below a
certain threshold are set to non-numeric values (“NaN”). These
structures actually can be fluorescent; however, their brightness
is lower compared to the target structure, i.e., the vessel wall. To
compare subtraction of a background region and image segmen-
tation, we applied both methods to cGi500 recordings in cultured
cells. Subtraction of a background region results in greater
changes of the baseline-normalized CFP/YFP ratio (R/R) as
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compared to ratio changes obtained through image segmentation
(Figure 5A, compare left and right traces), most likely as a direct
result of different background treatment. However, when the
dynamic binary mask is used, varying proportions of dim/non-
fluorescent background within the ROI do not affect noise levels
(Figure 5A, compare right traces from small and large ROI),
which can be an advantage over the background subtraction
method (Figure 5A, compare left traces from small and large
ROI). Consequently, ROIs can now be defined to contain large
and/or variable proportions of dim/non-fluorescent background
without affecting signal quantification. Using this approach with
DSC recordings markedly reduced the confounding drop of CFP
and YFP fluorescence upon vasodilation that was observed when
a background region was subtracted (Figure 5B). This alternative
evaluation strategy eventually allowed us to detect cGMP tran-
sients in the vascular wall during vasodilation in vivo. Control
injection of saline caused a transient vasodilation, most likely due
to an increase in blood volume (data not shown) that was not
associated with CFP/YFP ratio changes [Figure 5B, right, applica-
tion (1)]. Injection of DEA/NO caused vasodilation (Figure 3E)
that was associated with a clear R/R increase indicating an
increase of cGMP levels [Figures 3E and 5B, right, applications
(2) and (3)]. Relative vessel diameters were extracted from
dynamic binary masks via kymographs (Figure 3D). The extent
of NO-induced cGMP elevations measured with the cGi500
sensor correlated well with the extent of vasodilation (Figure 3E).
Thus, data evaluation with the image segmentation method
made it possible to observe cGMP transients in dilating vessels
(Figures 3B–E).
The highest CFP/YFP ratio changes observed in the DSC
model were relatively moderate (∼10%) compared to changes
recorded in the cremaster microvasculature (∼50%). Although
we cannot exclude biological reasons, this discrepancy is likely
caused by different ways of sensor excitation (single photon vs.
MP) and data evaluation (treatment of background fluorescence).
While image segmentation of DSC recordings was performed
without background subtraction, non-specific fluorescence from
a background region was subtracted in cremaster recordings. As
Figure 5 clearly shows, the evaluation strategy strongly affects
R/R values. Therefore, quantitative comparisons are only fea-
sible between experiments evaluated with the same strategy. Note
that omitting background subtraction during image segmenta-
tion may introduce variability if the background varies consider-
ably between experiments.We are working on further refinements
of our evaluation approach and expect substantial improvements
with the use of mice expressing cGi500 in a cell type-specific man-
ner (see Figure 2D). Another difference was that single-photon
excitation was used for cremaster imaging and MP excitation in
the DSC model. For the latter, we tested excitation wavelengths
between 820 and 880 nm and we have chosen 850 nm for best
imaging results (data not shown). Due to overlapping excitation
spectra of CFP and YFP and the non-linearity of MP excitation,
MP lasers likely cause direct excitation of the acceptor fluo-
rophore, YFP (Zipfel et al., 2003; Svoboda and Yasuda, 2006). We
assume that direct YFP excitation as well as bleed-through of CFP
emission into the YFP channel were, at least in part, responsible
for the relatively lowR/R values observed duringMP imaging in
the DSCmodel. In order to apply correction algorithms for tissue-
intrinsic background fluorescence or spectral bleed-through, or
to perform spectral unmixing, samples containing either no, or
only the donor or the acceptor fluorophore need to be recorded
(Van Rheenen et al., 2004; Thaler et al., 2005; Thaler and Vogel,
2006; Zhang et al., 2010; Zeug et al., 2012; Mauban et al., 2014). In
addition, alternative methods to estimate FRET efficiencies such
as fluorescence lifetime imaging microscopy (FLIM) are available
(Yasuda et al., 2006; Levitt et al., 2009; Fruhwirth et al., 2011).
However, recording appropriate donor- or acceptor-containing
specimens, or using FLIM techniques with non-optimized FRET
pairs can be challenging under in vivo conditions (Niesner and
Hauser, 2011; Geiger et al., 2012; Kamioka et al., 2012).
In the DSC model, animals can be analyzed repeatedly for up
to 5 weeks, which is an advantage over the cremaster model. The
DSC model allows longitudinal studies in individual animals, for
example, to follow disease progression. Thereby, animal numbers
can be reduced, while statistical power is maintained. Another
advantage over the cremaster model is that tissues within the
DSC are not acutely touched when imaging is performed. Under
the conditions described here, test drugs are delivered intra-
venously. Due to volume restrictions, this limits the number of
drug applications during an imaging session to about three to five.
Depending on the experimental question, systemic drug delivery
might complicate data interpretation. If so, the DSC model can
also be used for direct topical application of test compounds. To
this end, the coverslip is carefully removed to visualize vessels and
other structures while applying solutions that contain test com-
pounds (Fukumura et al., 1997). A number of protocols exist to
implant windows at different sites of the body (Jain et al., 2010;
Ritsma et al., 2012). This flexibility allows studying cGMP and
other signaling molecules in diverse vascular beds, such as cere-
bral vessels and the vasculature of abdominal or thoracic organs.
For these experiments, the setup has to reach sufficient scanning
speeds to resolve the kinetics of the biochemical/physiological
processes under investigation. Acquisition speed is especially
important when moving cells (e.g., in the blood) or structures
(e.g., the beating heart) are analyzed. Here, camera-based systems
have an advantage as they typically allow faster acquisition rates
(Stephens and Allan, 2003). For some IVM applications, spinning
disk systems might be a suitable alternative to MP systems (Jenne
et al., 2011), particularly when combined with MP excitation,
thereby achieving large penetration depths and fast acquisition
rates (Shimozawa et al., 2013). Alternatively, resonant galvanome-
ter mirror scanning enables MP microscopy at high speeds to
monitor fast biological processes (Kirkpatrick et al., 2012).
CONCLUSION AND OUTLOOK
Correlative IVM of biochemical processes and physiological
responses is a powerful technique to study cardiovascular biol-
ogy in vivo. Although technically challenging, experiments per-
formed in living animals are essential to analyze the functional
relevance of proteins and signaling molecules in health and
disease. We have generated and characterized transgenic mice
expressing the FRET-based cGMP biosensor cGi500 in the vas-
culature. Indeed, intravital FRET imaging combined with an
image-processing routine that accounts for tissue motion allowed
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us to monitor cGMP signals and associated vasodilation simulta-
neously in living mice. These and similar mouse models should
be useful to investigate the crosstalk between vascular cGMP,
cAMP, and Ca2+ signaling. For these and other studies, it will
be important to proof the selectivity of the cGi500 sensor for
detection of cGMP over cAMP in vivo, for example, by using
cAMP-increasing agents and pharmacological/genetic inhibition
of NO-induced cGMP synthesis. In the future, cGi500-expressing
mice can be used to visualize cGMP selectively in defined cell
types of the vessel wall, such as endothelial cells or SMCs,
or to analyze cGMP signaling in mouse models of cardiovas-
cular disorders. Another step to take is the precise quantifi-
cation of cGMP concentrations within the vasculature under
basal and stimulated conditions in vivo, as it has recently been
described for Ca2+ (Mauban et al., 2014). The combination of
genetic mouse models, optical biosensors, and state-of-the-art
IVM methods should soon allow us to “watch” biochemistry,
(patho-)physiology, and pharmacotherapy in the context of a
living mammalian organism.
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